) to beat earnings expectations when it reports first-quarter
2013 results after the closing bell on Apr 23, 2013.
Why a Likely Positive Surprise?
Our proven model shows that Amgen has the right combination of
two key ingredients to beat earnings.
Positive Zacks ESP
: The earnings Expected Surprise Prediction (ESP) (Read: Zacks
Earnings ESP: A Better Method
) for Amgen is +1.14% - the difference between the Most Accurate
earnings estimate of $1.77 per share and the Zacks Consensus
Estimate of $1.75 per share. This indicates a likely positive
Zacks Rank #3 (Hold)
: Note that stocks with Zacks Rank of #1, #2 and #3 have a
significantly higher chance of beating earnings. The Sell rated
stocks (#4 and #5) should never be considered while going into an
The combination of its Zacks Rank and Earnings ESP for Amgen
makes us confident of a positive earnings surprise in the
Drivers of Better-than-Expected Earnings
This biotech company has delivered positive earnings surprises in
three of the last four quarters with an average beat of 11.43%.
Key growth drivers at Amgen include Enbrel, Xgeva and Prolia.
We are also impressed by Amgen's efforts to expand in key
markets. Moreover, the company's moves to launch new
manufacturing technologies coupled with the efforts to develop
its pipeline are encouraging.
Other Stocks to Consider
Amgen is not the only company looking up this earnings season.
Here are some other stocks you may want to consider as our model
shows these have the right combination of elements to post an
earnings beat this season:
Gilead Sciences Inc.
) has an Earnings ESP of +2.08% and carries a Zacks Rank #3
Eli Lilly and Company
) has an Earnings ESP of +3.85% and holds a Zacks Rank #3 (Hold).
) has an Earnings ESP of +11.77% and holds a Zacks Rank #3
AMGEN INC (AMGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.